✦ LIBER ✦

Epigenetic therapy in MDS and AML: focus on decitabine

✍ Scribed by M. Lübbert; P. W. Wijermans

Book ID: 105988752
Publisher: Springer
Year: 2006
Tongue: English
Weight: 45 KB
Volume: 85
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-006-0100-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epigenetic therapy in MDS and acute AML:

Epigenetic therapy in MDS and acute AML: focus on decitabine

✍ M. Lübbert; P. W. Wijermans 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 74 KB

Epigenetic changes in therapy-related MD

Epigenetic changes in therapy-related MDS/AML

✍ Maria Teresa Voso; Francesco D’Alò; Mariangela Greco; Emiliano Fabiani; Marianna 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Emerging Role of Epigenetic Therapy: Foc

Emerging Role of Epigenetic Therapy: Focus on Decitabine

✍ Jean-Pierre J. Issa; Hagop M. Kantarjian 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 49 KB

[Advances in Experimental Medicine and B

[Advances in Experimental Medicine and Biology] Epigenetic Alterations in Oncogenesis Volume 754 || Epigenetic Therapies in MDS and AML

✍ Karpf, Adam R. 📂 Article 📅 2012 🏛 Springer New York ⚖ 439 KB

Molecular pathways mediating MDS/AML wit

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations

✍ Yuka Harada; Hironori Harada 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract AML1/RUNX1 point mutations have been identified in myelodysplastic syndrome (MDS) and MDS‐related acute myeloid leukemia (AML), or MDS/AML, and are distributed throughout the full length of __AML1/RUNX1__. Gene mutation is proposed to be one of the disease‐defining genetic abnormalities

Therapy-related MDS: the importance of r

✍ Prashant Sharma, Meet Kumar, Meena Lall, Lalit Kumar… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 300 KB